Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Section 6 of 6

References

177 sources

  1. Aelvoet et al. (2022) (opens in a new tab)
  2. Agresta et al. (2018) (opens in a new tab)
  3. Alberta Health Services clinical practice guideline SAR-004 (2025) (opens in a new tab)
  4. Anneberg et al. (2022) (opens in a new tab)
  5. Aung et al. (2018) (opens in a new tab)
  6. Bektas et al. (2023) (opens in a new tab)
  7. Bocale et al. (2011) (opens in a new tab)
  8. Bonvalot et al. (2023) (opens in a new tab)
  9. Bouhamama et al. (2023) (opens in a new tab)
  10. Brueckl et al. (2005) (opens in a new tab)
  11. Bui et al. (2025) (opens in a new tab)
  12. Cazzato et al. (2022) (opens in a new tab)
  13. Chetan et al. (2025) (opens in a new tab)
  14. Chugh et al. (2025) (opens in a new tab)
  15. Chugh et al. (2026) (opens in a new tab)
  16. Cigna nirogacestat coverage policy (2025) (opens in a new tab)
  17. ClinicalTrials.gov NCT01986218 (opens in a new tab)
  18. ClinicalTrials.gov NCT02476305 (opens in a new tab)
  19. ClinicalTrials.gov NCT04871282 (opens in a new tab)
  20. ClinicalTrials.gov NCT04871282 version 35 (opens in a new tab)
  21. ClinicalTrials.gov NCT04871282 version 37 (opens in a new tab)
  22. ClinicalTrials.gov NCT06677996 (opens in a new tab)
  23. ClinicalTrials.gov NCT06841315 (opens in a new tab)
  24. ClinicalTrials.gov NCT06845852 (opens in a new tab)
  25. ClinicalTrials.gov NCT06855264 (opens in a new tab)
  26. ClinicalTrials.gov NCT07610005 (opens in a new tab)
  27. Cojocaru et al. (2022) (opens in a new tab)
  28. Colombo et al. (2013) (opens in a new tab)
  29. Colombo et al. (2022) (opens in a new tab)
  30. Colombo et al. (2025) (opens in a new tab)
  31. Colombo et al. (2026) (opens in a new tab)
  32. Constantinidou et al. (2009) (opens in a new tab)
  33. Costa et al. (2025) (opens in a new tab)
  34. Crago et al. (2013) (opens in a new tab)
  35. Debaudringhien et al. (2022) (opens in a new tab)
  36. Desmoid Tumor Working Group (2020) (opens in a new tab)
  37. Dossa et al. (2026) (opens in a new tab)
  38. Drabbe et al. (2023) (opens in a new tab)
  39. Elnekave et al. (2022) (opens in a new tab)
  40. EMA Ogsiveo EPAR (2025) (opens in a new tab)
  41. EMA orphan designation EU/3/25/3127 (2025) (opens in a new tab)
  42. EU Clinical Trials Information System 2024-515909-26-00 (opens in a new tab)
  43. EU Clinical Trials Information System 2024-515909-26-00 API record (opens in a new tab)
  44. Express Scripts nirogacestat criteria (2023) (opens in a new tab)
  45. FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005) (opens in a new tab)
  46. FDA orphan drug designation record for varegacestat (2023) (opens in a new tab)
  47. Federman (2022) (opens in a new tab)
  48. FEP Blue nirogacestat policy 5.21.217 (2026) (opens in a new tab)
  49. Fernandez et al. (2023) (opens in a new tab)
  50. Fetterly et al. (2026) (opens in a new tab)
  51. Fiore et al. (2014) (opens in a new tab)
  52. Fiore et al. (2015) (opens in a new tab)
  53. Fiore et al. (2025) (opens in a new tab)
  54. Florida Medicaid oncology prior authorization criteria (2026) (opens in a new tab)
  55. Fouks et al. (2021) (opens in a new tab)
  56. G-BA justification to the resolution on nirogacestat (2026) (opens in a new tab)
  57. G-BA resolution on nirogacestat (2026) (opens in a new tab)
  58. Garbay et al. (2012) (opens in a new tab)
  59. Garcia-Ortega et al. (2020) (opens in a new tab)
  60. Garg et al. (2022) (opens in a new tab)
  61. Gounder (2026b) (opens in a new tab)
  62. Gounder et al. (2018) (opens in a new tab)
  63. Gounder et al. (2020) (opens in a new tab)
  64. Gounder et al. (2023a) (opens in a new tab)
  65. Gounder et al. (2023b) (opens in a new tab)
  66. Gounder et al. (2023c) (opens in a new tab)
  67. Gounder et al. (2025) (opens in a new tab)
  68. Gounder et al. (2026a) (opens in a new tab)
  69. Gronchi et al. (2021) (opens in a new tab)
  70. Hamada et al. (2014) (opens in a new tab)
  71. Hansmann et al. (2004) (opens in a new tab)
  72. Hohenberger et al. (2024) (opens in a new tab)
  73. Huang et al. (2023) (opens in a new tab)
  74. Husson et al. (2019) (opens in a new tab)
  75. Immunome corporate presentation, October 2026 (2026) (opens in a new tab)
  76. Immunome expanded access policy (opens in a new tab)
  77. Immunome Form 10-K (2026) (opens in a new tab)
  78. Immunome Form 10-Q, second quarter 2026 (2026) (opens in a new tab)
  79. Immunome Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
  80. Immunome press release, EMA validation of MAA (2026) (opens in a new tab)
  81. Immunome press release, ESMO 2026 data (2026) (opens in a new tab)
  82. Immunome press release, FDA acceptance of NDA (2026) (opens in a new tab)
  83. Immunome press release, first quarter 2026 results (2026) (opens in a new tab)
  84. Immunome press release, full year 2025 results (2026) (opens in a new tab)
  85. Immunome press release, J.P. Morgan 2025 pipeline update (2025) (opens in a new tab)
  86. Immunome press release, NDA submission (2026) (opens in a new tab)
  87. Immunome press release, RINGSIDE data at ASCO 2026 (2026) (opens in a new tab)
  88. Immunome press release, RINGSIDE topline results (2025) (opens in a new tab)
  89. Immunome press release, second quarter 2025 results (2025) (opens in a new tab)
  90. Immunome press release, second quarter 2026 results (2026) (opens in a new tab)
  91. Immunome press release, third quarter 2025 results (2025) (opens in a new tab)
  92. Immunome press release, third quarter 2026 results (2026) (opens in a new tab)
  93. Immunome topline call presentation (2025) (opens in a new tab)
  94. Ingley et al. (2019) (opens in a new tab)
  95. Janssen et al. (2017) (opens in a new tab)
  96. Johns et al. (2023) (opens in a new tab)
  97. Kasper et al. (2017a) (opens in a new tab)
  98. Kasper et al. (2017b) (opens in a new tab)
  99. Kasper et al. (2023) (opens in a new tab)
  100. Kasper et al. (2024a) (opens in a new tab)
  101. Kasper et al. (2024b) (opens in a new tab)
  102. Kasper et al. (2024c) (opens in a new tab)
  103. Kasper et al. (2026) (opens in a new tab)
  104. Keus et al. (2013) (opens in a new tab)
  105. Kornreich et al. (2023) (opens in a new tab)
  106. Kubicek et al. (2026) (opens in a new tab)
  107. Kummar et al. (2017) (opens in a new tab)
  108. Kurtz et al. (2021) (opens in a new tab)
  109. Lazar et al. (2008) (opens in a new tab)
  110. Loggers et al. (2024) (opens in a new tab)
  111. Lucas et al. (2025) (opens in a new tab)
  112. Malaviya et al. (2025) (opens in a new tab)
  113. Mandel et al. (2022) (opens in a new tab)
  114. Matsunobu et al. (2020) (opens in a new tab)
  115. Merck KGaA annual report 2025 (2026) (opens in a new tab)
  116. Merck KGaA press release, first quarter 2026 results (2026) (opens in a new tab)
  117. Merck KGaA press release, second quarter 2026 results (2026) (opens in a new tab)
  118. Merck KGaA press release, third quarter 2026 results (2026) (opens in a new tab)
  119. National Cancer Institute Thesaurus (opens in a new tab)
  120. NCODA PQI in Action, nirogacestat (2025) (opens in a new tab)
  121. NICE TA1199 committee discussion (2026) (opens in a new tab)
  122. NICE TA1199 information about nirogacestat (2026) (opens in a new tab)
  123. NICE TA1199 recommendations (2026) (opens in a new tab)
  124. NICE TA1199 resource impact summary report (2026) (opens in a new tab)
  125. Nieuwenhuis et al. (2008) (opens in a new tab)
  126. Nieuwenhuis et al. (2011) (opens in a new tab)
  127. Nishida et al. (2015) (opens in a new tab)
  128. Nishida et al. (2020) (opens in a new tab)
  129. Noujaim et al. (2024) (opens in a new tab)
  130. Oregon Medicaid prior authorization criteria (2025) (opens in a new tab)
  131. Palassini et al. (2017) (opens in a new tab)
  132. Penel et al. (2011) (opens in a new tab)
  133. Penel et al. (2017) (opens in a new tab)
  134. Penel et al. (2022) (opens in a new tab)
  135. Penel et al. (2023) (opens in a new tab)
  136. Perrier et al. (2018) (opens in a new tab)
  137. Quast et al. (2016) (opens in a new tab)
  138. Quintini et al. (2012) (opens in a new tab)
  139. Ratan et al. (2025) (opens in a new tab)
  140. Ratan et al. (2026) (opens in a new tab)
  141. Riedel et al. (2022) (opens in a new tab)
  142. Rigaux et al. (2015) (opens in a new tab)
  143. Rutherford et al. (2026) (opens in a new tab)
  144. Rutkowski et al. (2026) (opens in a new tab)
  145. Salas et al. (2011) (opens in a new tab)
  146. Saraf et al. (2025) (opens in a new tab)
  147. Sbaraglia et al. (2021) (opens in a new tab)
  148. Schut et al. (2022a) (opens in a new tab)
  149. Schut et al. (2022b) (opens in a new tab)
  150. Schut et al. (2023a) (opens in a new tab)
  151. Schut et al. (2023b) (opens in a new tab)
  152. Shaikh et al. (2024) (opens in a new tab)
  153. Shatnawei et al. (2013) (opens in a new tab)
  154. Shimizu et al. (2020a) (opens in a new tab)
  155. Shimizu et al. (2020b) (opens in a new tab)
  156. Singh et al. (2026) (opens in a new tab)
  157. Skapek et al. (2007) (opens in a new tab)
  158. Skapek et al. (2013) (opens in a new tab)
  159. Souza et al. (2023) (opens in a new tab)
  160. SpringWorks Connecticut OGSIVEO price disclosure (2026) (opens in a new tab)
  161. SpringWorks OGSIVEO prescribing information (2026) (opens in a new tab)
  162. SpringWorks Therapeutics Form 10-K (2025) (opens in a new tab)
  163. Tan et al. (2026) (opens in a new tab)
  164. Thomas et al. (2026) (opens in a new tab)
  165. Timbergen et al. (2018) (opens in a new tab)
  166. Toulmonde et al. (2019) (opens in a new tab)
  167. van Broekhoven et al. (2015) (opens in a new tab)
  168. van der Graaf et al. (2026) (opens in a new tab)
  169. van Houdt et al. (2019) (opens in a new tab)
  170. Vermont Attorney General new drug report (2024) (opens in a new tab)
  171. Villalobos et al. (2018) (opens in a new tab)
  172. Wang et al. (2012) (opens in a new tab)
  173. Wang et al. (2026) (opens in a new tab)
  174. WHO Proposed INN List 130 (2023) (opens in a new tab)
  175. WHO Recommended INN List 92 (2024) (opens in a new tab)
  176. Xu et al. (2026) (opens in a new tab)
  177. Zare et al. (2026) (opens in a new tab)